Adrenergic receptors belong to the superfamily of G protein-coupled receptors and constitute the molecular basis underlying the pharmacological actions of norepinephrine tartrate. Differences in tissue distribution and downstream signalling pathways across receptor subtypes determine the targeted therapeutic effects of the drug. Following intravenous entry into the circulation, the drug rapidly diffuses to target tissues including systemic blood vessels, the heart and nerve terminals, where it binds specifically to cognate receptors and initiates downstream signal transduction.

α₁ receptors are abundantly expressed on the cell membranes of vascular smooth muscle in systemic arterioles and venules, with the highest density in cutaneous and mucosal vessels, renal vessels, mesenteric vessels, cerebral vessels and skeletal muscle vasculature.

Binding of it to α₁ receptors activates receptor-coupled Gq proteins and triggers downstream signalling cascades; this represents the core mechanism mediating vasoconstriction and increased peripheral vascular resistance. α₂ receptors are predominantly located on the presynaptic membrane of sympathetic nerve terminals, with minor expression in the central nervous system and vascular smooth muscle.

Upon binding to presynaptic α₂ receptors, the drug activates inhibitory Gi proteins to exert negative feedback regulation, suppressing further release of endogenous norepinephrine from sympathetic nerve terminals, preventing excessive sympathetic activation and enabling self-regulation of pharmacological effects.

β₁ receptors are concentrated mainly on cardiomyocyte membranes, the sinoatrial node and the atrioventricular node.

Drug binding to β₁ receptors activates Gs proteins to mediate downstream signalling and gently modulate myocardial contractility and heart rate. Because the drug exhibits substantially lower affinity for β₁ receptors than for α receptors, its cardiac stimulant effect is weaker than its vasoconstrictive effect, and significant tachycardia does not occur. This constitutes a key reason for its superior haemodynamic stability relative to other catecholamines in clinical practice.

(I) Mechanism of Peripheral Vasoconstriction and Peripheral Resistance Regulation

The vascular system is the principal target of it. The drug elicits potent, broad-spectrum vasoconstriction by fully activating α₁ receptors on vascular smooth muscle. At the microcirculatory level, constriction of arterioles, the resistance vessels, markedly elevates total peripheral resistance; constriction of venules, the capacitance vessels, reduces peripheral blood pooling and increases venous return. Together these two effects regulate circulating blood volume and arterial pressure.

Vascular responsiveness varies in a graded fashion across tissues.

Cutaneous and mucosal vasoconstriction is most pronounced, effectively improving peripheral perfusion and reversing the cool, clammy skin seen in shock.

Renal and mesenteric vasoconstriction is intermediate, redirecting blood away from less vital visceral beds to prioritise perfusion of the heart and brain. Constrictive effects on cerebral and coronary vessels are weak; compensatory blood pressure elevation instead improves perfusion in these territories. This pattern of targeted vasoconstriction precisely reverses shock-related vasodilation and reduced peripheral resistance, rapidly raises mean arterial pressure and re-establishes a stable systemic pressure gradient.

(II) Mechanism of Bidirectional Cardiac Regulation

Norepinephrine tartrate exerts bidirectional cardiac effects comprising direct pharmacological action and indirect reflex modulation. Directly, the drug activates myocardial β₁ receptors, stimulating intracellular adenylyl cyclase, raising cyclic adenosine monophosphate (cAMP) concentrations, enhancing transmembrane calcium influx and thereby increasing myocardial contractility, accelerating conduction and moderately raising stroke volume.

The indirect reflex pathway dominates cardiac regulation. Potent peripheral vasoconstriction induced by the drug rapidly elevates arterial pressure, stimulating baroreceptors in the carotid sinus and aortic arch, activating the vagal reflex and suppressing sympathetic outflow.

The net result is bradycardia and reduced myocardial oxygen demand. This combined "positive inotropy plus heart-rate slowing" profile allows blood pressure augmentation without substantially increasing cardiac load, effectively reducing adverse events such as tachyarrhythmias and myocardial ischaemia. It is therefore suitable for patients with shock or hypotension complicated by cardiac dysfunction.

Overall, the drug exerts a modest effect on cardiac output, supporting circulatory stabilisation while preserving steady cardiac performance.

(III) Mechanism of Neuroendocrine Negative Feedback

Beyond peripheral circulatory effects, the drug initiates neuroendocrine negative feedback by activating presynaptic α₂ receptors on sympathetic nerve terminals. α₂ receptor activation acts via Gi proteins to inhibit adenylyl cyclase, lower intraterminal cAMP concentrations, reduce calcium influx and suppress vesicular release of neurotransmitters.

This blocks excessive secretion of endogenous norepinephrine and epinephrine.The mechanism balances the pressor effect of exogenous drug to prevent excessive hypertension, while restraining sustained sympathetic overactivation and limiting catecholamine-mediated vasospasm and myocardial injury, thereby maintaining neuroendocrine homeostasis.

The macroscopic pharmacological effects of it arise fundamentally from activation of specific intracellular signalling cascades in target cells. Distinct G protein coupling across receptor subtypes produces divergent cellular responses, forming the complete molecular mechanism of action.

α₁ receptor-mediated vasoconstrictive pathway: drug binding to α₁ receptors activates Gq proteins, promoting hydrolysis of phosphatidylinositol bisphosphate into inositol trisphosphate (IP₃) and diacylglycerol (DAG). IP₃ triggers calcium release from intracellular stores and raises cytosolic free calcium concentrations;DAG activates protein kinase C and synergistically amplifies calcium-dependent contractile responses.

Calcium binds to troponin, driving myofilament sliding in vascular smooth muscle and ultimately causing vasoconstriction and increased peripheral resistance.

α₂ receptor-mediated inhibitory pathway: activated α₂ receptors couple to Gi proteins, inhibiting adenylyl cyclase, lowering intracellular cAMP, reducing protein kinase A activity, diminishing calcium influx at nerve terminals and suppressing neurotransmitter release to complete negative feedback. This pathway also mildly limits excessive vascular smooth muscle contraction, balancing the powerful constrictive signal from α₁ receptors and avoiding microcirculatory occlusion.

β₁ receptor-mediated myocardial regulatory pathway: activated β₁ receptors couple to Gs proteins, stimulating adenylyl cyclase, raising myocardial cAMP levels and activating protein kinase A. This opens L-type calcium channels on cardiomyocyte membranes, increases calcium influx and enhances contractility; it also accelerates sinoatrial automaticity and atrioventricular conduction to produce mild positive inotropy. The pathway's direct effect is modest and partially counteracted by the vagal baroreflex triggered by blood pressure elevation, so excessive cardiac stimulation does not occur.